Anticancer Potential of Thymoquinone: A Novel Bioactive Natural Compound from Nigella sativa L

Anticancer Agents Med Chem. 2022;22(20):3401-3415. doi: 10.2174/1871520622666220511233314.

Abstract

Cancer involves the uncontrolled division of cells resulting in abnormal cell growth due to various gene mutations and is considered the second major cause of death. Due to drug resistance to current anticancer drugs, cancer incidence is rising, and seeking effective treatment is a major concern. Natural products are prospective to yield unique molecules, as nature is a leading source of various drug molecules due to plenty of pharmacologically active molecules. Thymoquinone, a bioactive constituent obtained from Nigella sativa L., has drawn considerable attention among researchers in recent years due to its anticancer potential involving various molecular targets, including initiation of apoptosis initiation, arrest of cell cycle and generation of ROS, besides targeting multiple kinases such as tyrosine kinase, MAPK, and Janus kinase. The current review summarizes the thymoquinone chemistry, sources and anticancer potential involving various molecular targets.

Keywords: Janus kinase; Nigella sativa; anticancer therapeutics; apoptosis; plant products; thymoquinone.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • Benzoquinones / chemistry
  • Biological Products* / pharmacology
  • Biological Products* / therapeutic use
  • Humans
  • Janus Kinases / therapeutic use
  • Neoplasms* / drug therapy
  • Nigella sativa* / chemistry
  • Prospective Studies
  • Reactive Oxygen Species

Substances

  • thymoquinone
  • Reactive Oxygen Species
  • Benzoquinones
  • Biological Products
  • Antineoplastic Agents
  • Janus Kinases